GSK
Diabetes trial disappointment for GSK and Tolerx
March 14, 2011Research and Development DEFEND-1, DEFEND-2, GSK, GlaxoSmithKline, Tolerx, diabetes, otelixizumab, type I diabetes
GSK and Tolerx’s type I diabetes drug otelixizumab has failed to meet its primary endpoint in a late-stage trial. Anti-CD3 …
US approval for GSK’s lupus treatment Benlysta
March 10, 2011Sales and Marketing Benlysta, GSK, GlaxoSmithKline, Human Genome Sciences, Lupus, belimumab, systemic lupus erythematosus
GlaxoSmithKline’s lupus treatment Benylsta has won an historic approval in the US, but will have to prove its safety record …
GSK ends neuroscience research alliance
March 7, 2011Research and Development GSK, GlaxoSmithKline, Targacept, neuronal nicotinic receptors, neuroscience research
GlaxoSmithKline has severed a strategic alliance formed in July 2007 with US biopharma company Targacept. GSK forked out $45 million …
GSK adds former Merck CFO to board
March 7, 2011Sales and Marketing GSK, GlaxoSmithKline, Judy Lewent, Stacey Cartwright, appointment, sales and marketing
GlaxoSmithKline has appointed Judy Lewent to its board as a non-executive director. She has previously served as an executive VP …
GSK to reimburse tuition fees for UK trainees
March 3, 2011Business Services, Research and Development, Sales and Marketing GSK, GlaxoSmithKline, UK science, careers, graduate, graduate recruitment
GlaxoSmithKline is set to reimburse UK university tuition fees paid by its trainees from 2012. Each year, GSK recruits between …
GlaxoSmithKline seeks alliances with ‘academic superstars’
March 2, 2011Research and Development GSK, GlaxoSmithKline, Pentraxin Therapeutics, academia, al Free and University College Medical School, universities
GlaxoSmithKline has unveiled a partnership with a ‘superstar academic’, as part of a new strategy which it believes will help …
David Redfern appointed ViiV chairman
February 28, 2011Research and Development, Sales and Marketing David Redfern, GSK, GlaxoSmithKline, Pfizer, ViiV, ViiV Healthcare, appointment, research and development, sales and marketing
David Redfern has been appointed as chairman of ViiV Healthcare, the joint GlaxoSmithKline-Pfizer venture focused on HIV.
NICE yes for Votrient, no to Avastin
February 23, 2011Sales and Marketing Cancer, GSK, GlaxoSmithKline, Kidney cancer, NICE, Roche, avastin, bevacizumab, breast cancer
NICE has recommended GlaxoSmithKline’s kidney cancer drug Votrient on the same day it gave a final negative decision to Roche’s …
WHO wants narcolepsy link with swine flu vaccine investigated
February 10, 2011Research and Development, Sales and Marketing Finland Institute, GSK, GlaxoSmithKline, Pandemrix, narcolepsy, swine flu
The World Health Organisation has called for further investigation into GSK’s swine flu vaccine link to sleeping disorder narcolepsy, following …
GSK profits slump amid ongoing Avandia woes
February 7, 2011Sales and Marketing 2010 pharma results, Avandia, GSK, GlaxoSmithKline
GlaxoSmithKline’s ongoing woes with diabetes drug Avandia hit profits in 2010. Profits after tax plummeted 56% to £3 billion for …
GSK settles Avandia case out of court
February 1, 2011Sales and Marketing Avandia, GSK, diabetes
GlaxoSmithKline this week settled a US federal lawsuit regarding its diabetes drug Avandia before it went to court. The company …
GSK and Actelion drop insomnia treatment
January 30, 2011Research and Development Actelion, GSK, insomnia
Actelion and GlaxoSmithKline are to abandon development of phase III insomnia drug almorexant because of problems with side-effects.Almorexant a dual …
GSK skin cancer drugs moves into phase III
January 25, 2011Research and Development BRAF V600 mutation, Cancer, Duchenne Muscular Dystrophy, GSK, GSK1120212, GSK2118436, GSK968, GlaxoSmithKline, melanoma, skin cancer
GlaxoSmithKline has begun late-stage trials of two new drugs for advanced or metastatic melanoma patients. GSK2118436 and GSK1120212 are being …
GSK takes £2.2bn hit from Avandia claims
January 18, 2011Sales and Marketing Avandia, GSK, GlaxoSmithKline, rosiglitazone
GlaxoSmithKline’s Avandia woes are continuing, with the company admitting it expects to take a mammoth legal charge over the troubled …
Anti-cancer stem cell drug starts clinical trials
January 14, 2011Research and Development Cancer, GSK, GlaxoSmithKline, OMP-21M18, OMP-59R5, OncoMed, Stem cells, advanced solid tumour cancers
OncoMed and GSK’s novel anti cancer stem cell drug OMP-59R5 has begun clinical trials and could represent the future direction …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
